前药
化学
神经氨酸酶抑制剂
神经氨酸酶
烷基化
药品
立体化学
药理学
生物化学
酶
医学
疾病
2019年冠状病毒病(COVID-19)
病理
传染病(医学专业)
催化作用
出处
期刊:Yūki Gōsei Kagaku Kyōkaishi
[The Society of Synthetic Organic Chemistry, Japan]
日期:2014-01-01
卷期号:72 (10): 1097-1109
被引量:1
标识
DOI:10.5059/yukigoseikyokaishi.72.1097
摘要
Laninamivir Octanoate (Inavir®) (1) is the long-acting anti-influenza drug, and has been launched in 2010. It is the prodrug of laninamivir (2), which is a neuraminidase inhibitor, and it shows the clinically interesting drug profile such as “single inhaled administration for the treatment of influenza”. Herein, we describe the synthetic aspects for the drug discovery program on Laninamivir Octanoate (Inavir®) (1) and its related compounds, featuring 1) the introduction of fully-protected guanidyl group to C-4 position of laninamivir (2), 2) the synthesis of a variety of 7-modified sialic acids from 4-modified N-acetyl glucosamines and 4-modified N-acetyl mannnosamines via enzymatic aldol condensation using Neu5Ac aldolase, and 3) the development of direct alkylation to less reactive C-7 OH group of sialic acid. Also, we describe the topics on our derivatization diversified by these synthetic methods to discover Laninamivir Octanoate (Inavir®) (1).
科研通智能强力驱动
Strongly Powered by AbleSci AI